ENSC
Ensysce Biosciences, Inc.
ENSC's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over ENSC overall, supported by stronger fundamentals and stronger valuation.
ENSC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ENSC's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ENSC PE Valuation
ENSC has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ENSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect ENSC's losses to shrink, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ENSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.75 | +$8.47 |
| Q2 2026 | -$2.52 | +$9.36 |
| Q1 2026 | -$3.11 | +$11.28 |
| Q4 2025 | -$3.98 | +$17.27 |
| Q3 2025 | -$14.22 | +$7.68 |
| Q2 2025 | -$11.88 | +$24.12 |
| Q1 2025 | -$14.39 | +$33.01 |
| Q4 2024 | -$21.25 | +$49.10 |
ENSC lost $5.75 per share over the past year, a smaller loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ENSC on earnings quality, reporting a profit while its opponent remains loss making.
ENSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +342% |
| Q2 2026 | $1.2M | -15% |
| Q1 2026 | $961K | -27% |
| Q4 2025 | $1.9M | +44% |
| Q3 2025 | $493.1K | -86% |
| Q2 2025 | $1.4M | +654% |
| Q1 2025 | $1.3M | +332% |
| Q4 2024 | $1.3M | +153% |
ENSC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 342% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3781% | -3023 points |
| Q2 2026 | -221% | -94 points |
| Q1 2026 | -371% | -222 points |
| Q4 2025 | -148% | +127 points |
| Q3 2025 | -759% | -778 points |
| Q2 2025 | -128% | +948 points |
| Q1 2025 | -149% | +454 points |
| Q4 2024 | -274% | +338 points |
ENSC's operating margin was −3781% last quarter, down 3023 points from the same quarter a year ago, near the bottom of its range since 2021.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ENSC on profitability, with a higher operating margin.
ENSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$744.4K |
| Q1 2026 | -$3.5M | -$1.8M |
| Q4 2025 | -$1.5M | -$761.7K |
| Q2 2025 | -$2.7M | -$397K |
| Q1 2025 | -$1.7M | +$1.7M |
| Q4 2024 | -$764.1K | +$1M |
| Q3 2024 | -$1M | +$1.2M |
| Q2 2024 | -$2.3M | +$798.7K |
ENSC has the stronger cash trend. Its trailing FCF is up 6.3% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ENSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +40% | +5.2M shares |
| 1 year | +530% | +15.3M shares |
| 3 years | +25787% | +18.1M shares |
| 5 years | +985979% | +18.2M shares |
| Available history | +1077056% | +18.2M shares |
ENSC has 18M diluted shares, up 530% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $136.3M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ENSC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ENSC Net Leverage
ENSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ENSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 20.9 | Neutral |
ENSC's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ENSC PE vs Healthcare Sector
| Metric | ENSC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENSC has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ENSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 9.3% below |
| 20 week MA | $0.40 | 2.5% below |
| 50 week MA | $0.53 | 26% below |
| 100 week MA | $1.97 | 80% below |
| 200 week MA | $14.8 | 97% below |
ENSC is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ENSC on trend strength, trading above more of its moving averages.
ENSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37,224.0 | $47,808.0 | +28% |
| 2021 | $47,808.0 | $18,432.0 | -61% |
| 2022 | $18,432.0 | $129.6 | -99% |
| 2023 | $129.6 | $15.9 | -88% |
| 2024 | $15.9 | $8.88 | -44% |
| 2025 | $8.88 | $1.10 | -88% |
| 2026 YTD | $1.10 | $0.39 | -65% |
ENSC has finished five years in a row lower, and it's down 65% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ENSC on returns for 2026, with the stronger performance.